CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in hemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Paz-Ares, L.; Brahmer, J.; Hellmann, M. D.; Reck, M.; O'Byrne, K.; Borghaei, H.; Geese, W. J.; Lu, H.; Nathan, F. E.; Ramalingam, S. |
| Abstract Title: | CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in hemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) |
| Meeting Title: | 7th European Lung Cancer Conference (ELCC 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 May 5-8 |
| Meeting Location: | Geneva, Switzerland |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-04-01 |
| Start Page: | mdx091.064 |
| Language: | English |
| ACCESSION: | WOS:000405512800132 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx091.064 |
| Notes: | Meeting Abstract: 144TiP -- Appears on pages 50-51 of the abstract book -- Source: Wos |
